Head to head
Semaglutide against Adipotide
Adipotide produced dramatic weight loss in primates by attacking the blood supply of fat tissue, along with kidney toxicity, and never became a medicine. It is the useful counterexample to the idea that a large weight loss number is the thing that matters.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
AdipotideAdipotide (FTPP, fat-targeted proapoptotic peptide)
An experimental peptide that targets the blood supply of white fat, causing dramatic weight loss in primates but with significant kidney toxicity.
Side by side, on the facts we can check
| Attribute | Semaglutide | Adipotide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Not FDA-approved; experimental |
| Half-life | ~7 days | Short |
| Molecular weight | 4,113.6 Da | ~2,600 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | A targeting domain binds prohibitin on fat-tissue blood vessels and a proapoptotic domain disrupts those cells' mitochondria, starving fat depots of blood supply. |
| Human studies cited | 5 | 0 |
| Legal status, US | FDA-approved, prescription only | Not approved; research use only |
Frequently asked questions
What is the difference between Semaglutide and Adipotide?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Adipotide: An experimental peptide that targets the blood supply of white fat, causing dramatic weight loss in primates but with significant kidney toxicity.
Which has stronger research evidence, Semaglutide or Adipotide?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 0 of 2 for Adipotide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Adipotide FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Adipotide: Not FDA-approved; experimental.
Related posts
Blog articles that cover Semaglutide or Adipotide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.